Skip to main content
. Author manuscript; available in PMC: 2023 Jun 12.
Published in final edited form as: Mol Cancer Ther. 2022 Apr 1;21(4):535–545. doi: 10.1158/1535-7163.MCT-21-0728

Fig.2. induces autophagic cell death associated with downregulation of p53.

Fig.2

A, MMRi62 induces downregulation of p53 expression in pancreatic cancer cells. WB analysis of p53, MDM2 and MDM4 in Panc1 and BxPc3 treated for 24h with indicated concentrations of MMRi62 (μM). B, MMRi62 induces increased autophagy and apoptosis. WB analysis of p53, cleaved PARP and LC3 in Panc1 or BxPC3 cells treated with MMRi62 at indicated concentrations for 72h. C, IF staining of p53 and LC3 in Panc1 and BxPc3 after 72h treatment with 2mM MMRi62. D. MMRi62 treatment induces increase in cellular ROS after MMRi62 treatment at two concentrations for 72h. Left, Panc1, p=0.0003 and <0.0001 for C vs 2 and 4 μM MMRi62 respectively; right, BxPc3, p=<0.0001 for C vs 2 or 4 μM MMRi62 respectively.

HHS Vulnerability Disclosure